Quite possibly. It will have to be addressed sooner rather than later. Afrezza met all its endpoints from the trials and there don't seem to be any major issues clinically with the data. I'm sure other topics, in no particular order, will be cough, hypos, weight gain/loss, long term lung effects --- all of which will doubtless appear on any label. Also age and other limitations (smoking? asthma? possible drug interaction with other meds or inhalants?) Just throwing stuff up against the wall to see what, if anything, sticks folks.